A Phase 3, Multi-center, Double-blind, 2-part Study in Participants with KRAS G12C-Mutant, Non-Small Cell Lung Cancer Comparing the Efficacy and Safety of Olomorasib in Combination with Standard of Care to Placebo in Combination with Standard of Care as Adjuvant Treatment after Platinum-based Chemotherapy
- Sponsor:
- Eli Lilly
- Sponsor Study ID:
- SUNRAY-02 J3M-MC-JZQH
- CTO #:
- 104112
- NCT Number:
- NCT06890598
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- To compare the efficacy of Olomorasib in combination with pembrolizumab versus placebo with pembrolizumab.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Alexander, Mariam, at alexanma@musc.edu .
- Study Coordinator, Morgan, Shelby, at morshelb@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina